Morning Briefing on Pharma Equities -- Mylan, Actavis, Zoetis, Horizon Pharma, and Medicines
30 Apr, 2015, 09:10 ET
LONDON, April 30, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Actavis PLC (NYSE: ACT), Zoetis Inc. (NYSE: ZTS), Horizon Pharma PLC (NASDAQ: HZNP), and The Medicines Company (NASDAQ: MDCO). Free research report on Mylan can be accessed at http://get.Investor-Edge.com/pdf/?c=Mylan&d=30-Apr-2015&s=MYL. The US markets on Wednesday, April 29, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 18,035.53, down 0.41% and the NASDAQ Composite closed at 5,023.64, down 0.63%. The S&P 500 finished the session 0.37% lower at 2,106.85. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 841.03, down 0.80%, whereas the index has advanced 3.35% in the previous three months. Register for your complimentary reports at the links given below.
Mylan N.V.'s stock gained 2.46%, to close the day at $74.50. The stock recorded a trading volume of 10.42 million shares, above its three months average volume of 8.27 million shares. The company's shares oscillated between $72.07 and $74.72 during the session. Over the last one month and over the past three months, Mylan N.V.'s shares have surged 20.88% and 35.74%, respectively. Further, the stock has gained 32.16% since the start of this year. The company is trading above its 50-day and 200-day moving averages. Mylan N.V.'s 50-day moving average of $62.51 is above its 200-day moving average of $54.55. Additionally, the stock traded at a PE ratio of 24.85 and has a Relative Strength Index (RSI) of 60.95. Sign up and read the free notes on MYL at:
On Wednesday, shares in Actavis PLC recorded a trading volume of 2.19 million shares, lower than its three months average volume of 3.32 million shares. The stock ended the day at $288.23, which was 0.05% above its previous day's closing of $288.10, and registered an intraday range of $285.00 and $289.82. Shares of the company traded at a PE ratio of 117.35. Actavis PLC's shares have fallen by 2.43% in the previous three trading sessions, while the stock has gained 5.48% in the last three months and 11.97% on YTD basis. The company is trading above its 200-day moving average of $257.81, while the 200-day moving average is below the 50-day moving average of $297.06. Furthermore, shares of Actavis PLC have an RSI of 40.15. The complimentary notes on ACT can be downloaded as in PDF format at:
Zoetis Inc.'s stock fell 1.12% to end Wednesday's session at $45.22. The stock recorded a trading volume of 3.99 million shares, above its three months average volume of 3.37 million shares. The company's shares fluctuated between $45.10 and $45.94 during the session. Shares of the company traded at a PE ratio of 32.13. Zoetis Inc.'s shares have fallen by 2.16% over the last one month. However, the stock has advanced 4.39% in the previous three months and 5.09% since the beginning of 2015. The company is trading above its 200-day moving average. Zoetis Inc.'s 50-day moving average of $46.55 is above its 200-day moving average of $40.83. Additionally, the stock has an RSI of 41.74. Register for free on Investor-Edge and access the latest research on ZTS at:
On Wednesday, shares in Horizon Pharma PLC fluctuated between $28.82 and $29.66 before ending the session 1.05% lower at $29.26. The stock reported a trading volume of 3.42 million shares, lower than its three months average volume of 3.80 million shares. Shares of the company traded at a PE ratio of 584.09. Horizon Pharma PLC's stock has rallied 34.16% in the last one month, 71.31% in the previous three months, and 127.00% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $24.10 and $15.44, respectively. Moreover, shares of Horizon Pharma PLC have an RSI of 60.66. The complete research on HZNP is available for free at:
The Medicines Co.'s stock finished Wednesday's session 0.95% lower at $26.05. A total of 0.56 million shares were traded, which was below its three months average volume of 1.22 million shares. The stock vacillated between $25.81 and $26.51 during the session. Over the previous three trading sessions and over the last one month, The Medicines Co.'s shares have lost 4.96% and 8.92%, respectively. Additionally, from the beginning of 2015, the stock has fallen by 5.85%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $28.63 is greater than its 200-day moving average of $26.13. The Medicines Co.'s stock has an RSI of 36.06. Free in depth research on MDCO is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Share this article